A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a ...
A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a ...